文献速递淋巴瘤白血病造血干细胞移植与细胞治疗

Talicabtagene autoleucel治疗复发或难治性B细胞恶性肿瘤:一项开放标签、多中心、1/2期研究结果

Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study.
PubMed 文献 · Lancet Haematol · 2025-03-13

在印度六家三级癌症中心开展的开放标签、多中心1/2期研究,评估人源化抗CD19 4-1BB CAR-T细胞疗法talicabtagene autoleucel治疗复发或难治性B细胞恶性肿瘤。1期14例、2期50例,共64例。2期51例可评估疗效患者的总缓解率为73%(37/51;95%CI 59-83)。

要点

  • 1期14例患者中,2×10^6-17×10^6 CAR-T细胞/kg剂量下未发生剂量限制性毒性。
  • 57例安全性人群中,最常见的≥3级毒性为血液学事件:贫血35例(61%)、血小板减少37例(65%)、中性粒细胞减少55例(96%)、发热性中性粒细胞减少27例(47%)。
  • 51例可评估疗效患者的总缓解率为73%(37/51;95%CI 59-83)。

核心结论

  • Talicabtagene autoleucel具有可控的安全性,并在复发或难治性B细胞恶性肿瘤患者中诱导了持久缓解。
  • 该疗法满足了印度复发或难治性B细胞恶性肿瘤患者的重要未满足需求。

研究设计与样本

  • 开放标签、多中心、1/2期研究,在印度六家三级癌症中心开展。
  • 1期为单中心研究,在Tata Memorial Hospital开展,纳入年龄≥18岁的复发或难治性B细胞淋巴瘤患者。
  • 2期为单臂、多中心、篮式试验,在五家三级癌症中心开展,纳入年龄≥15岁的复发或难治性B细胞急性淋巴细胞白血病或B细胞淋巴瘤患者。
  • 1期14例(2021年5月11日至2022年5月13日入组),2期50例(2022年12月27日至2023年8月31日入组),共64例;中位年龄44岁(IQR 27-57),男性49例(77%)、女性15例(23%)。
  • 疗效分析在疗效可评估队列中进行(接受目标剂量及3天淋巴清除治疗的所有患者);安全性分析在安全性人群中进行(接受talicabtagene autoleucel的所有患者)。

主要发现

  • 1期中,2×10^6-17×10^6 CAR-T细胞/kg剂量下未发生剂量限制性毒性。
  • 基于7例中3例在此剂量达到完全缓解,2期选择至少5×10^6 CAR-T细胞/kg的剂量。
  • 最常见的≥3级毒性为血液学事件:贫血35/57例(61%)、血小板减少37/57例(65%)、中性粒细胞减少55/57例(96%)、发热性中性粒细胞减少27/57例(47%)。
  • 发生两例治疗相关死亡:一例死于发热性中性粒细胞减少、免疫效应细胞相关噬血细胞性淋巴组织细胞增生症和感染性休克;另一例死于肺出血、多器官功能障碍综合征和细胞因子释放综合征。
  • 51例疗效可评估患者(36例B细胞淋巴瘤和15例B细胞急性淋巴细胞白血病)中,总缓解率为73%(37/51;95%CI 59-83)。

关键数值与推荐

  • 1期:talicabtagene autoleucel 1×10^7-5×10^9 CAR-T细胞,分次输注(第0、1、2天分别给予10%、30%、60%)。
  • 2期:talicabtagene autoleucel至少5×10^6 CAR-T细胞/kg(最多2×10^9 CAR-T细胞),第0天输注。
  • 淋巴清除治疗:环磷酰胺500 mg/m2联合氟达拉滨30 mg/m2共3天,或苯达莫司汀90 mg/m2共2天。
  • 采集至少1×10^9淋巴细胞用于制造CAR-T细胞。
  • 入选标准:预期寿命≥12周;ECOG体能状态0-1(1期)或0-2(2期);器官功能充分。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In low-income and middle-income counties (LMICs), the outcome of relapsed or refractory B-cell malignancies is poor due to the absence of effective therapies. We report the results of a phase 1/2 study of a novel humanised anti-CD19 4-1BB chimeric antigen receptor (CAR) T-cell therapy, talicabtagene autoleucel, for patients with relapsed or refractory B-cell malignancies. METHODS: This open-label, multicentre, phase 1/2 study was done at six tertiary cancer centres in India. Phase 1 was a single-centre study done in Tata Memorial Hospital, India, in patients aged 18 years or older with relapsed or refractory B-cell lymphomas. Phase 2 was a single-arm, multicentre, basket trial done in five tertiary cancer centres in patients aged 15 years and older with relapsed or refractory B-cell acute lymphoblastic leukaemia or B-cell lymphoma. Eligible patients had a life expectancy of 12 weeks or more, an ECOG performance status of 0-1 (phase 1) or 0-2 (phase 2), and an adequate organ function. Patients underwent apheresis to obtain at least 1 × 109 lymphocytes to manufacture CAR T cells. Lymphodepletion therapy was done with cyclophosphamide 500 mg/m2 and fludarabine 30 mg/m2 for 3 days or bendamustine 90 mg/m2 for 2 days. Patients were then infused intravenously with talicabtagene autoleucel 1 × 107-5 × 109 CAR T cells in a fractionated schedule (10%, 30%, and 60%, on days 0, 1, and 2, respectively) during phase 1 or at least 5 × 106 CAR T cells per kg (up to 2 × 109 CAR T cells) on day 0 during phase 2. The primary endpoints were safety (phase 1) and overall response rate (phase 2). The efficacy analysis was done in the efficacy evaluable cohort (all patients who received the target dose and 3 days of lymphodepletion therapy). The safety analysis was done in the safety population (all patients who received talicabtagene autoleucel). The trials are registered with Clinical Trial Registry-India (CTRI/2021/04/032727 and CTRI/2022/12/048211), and enrolment is closed. FINDINGS: Of 64 patients, 14 were enrolled in phase 1 (from May 11, 2021, to May 13, 2022) and 50 were enrolled in phase 2 (Dec 27, 2022, to Aug 31, 2023). The median age of the overall cohort was 44 years (IQR 27-57), and 49 (77%) of 64 patients were male and 15 (23%) were female. In phase 1, no dose-limiting toxicities occurred at doses of 2 × 106-17 × 106 CAR T cells per kg. A dose of at least 5 × 106 CAR T cells per kg was chosen for phase 2 based on a complete response in three of seven patients at this dose. The most common grade 3 or worse toxicities were haematological events: anaemia (35 [61%] of 57 patients), thrombocytopenia (37 [65%] patients), neutropenia (55 [96%] patients, and febrile neutropenia (27 [47%]) patients). There were two treatment-related deaths, one due to febrile neutropenia, immune-effector cell associated haemophagocytic lymphohistiocytosis, and septic shock, and the second due to pulmonary bleed, multiorgan dysfunction syndrome, and cytokine release syndrome. In 51 efficacy-evaluable patients (36 with B-cell lymphoma and 15 with B-cell acute lymphoblastic leukaemia), the overall response rate was 73% (37 of 51; 95% CI 59-83). INTERPRETATION: Talicabtagene autoleucel had a manageable safety profile and induced durable responses in patients with relapsed or refractory B-cell malignancies. This therapy addresses an important unmet need for patients with relapsed or refractory B-cell malignancies in India. FUNDING: Immunoadoptive Cell Therapy (ImmunoACT) and Indian Council of Medical Research (ICMR).

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Jain H, Karulkar A, Kalra D, et al. Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study. Lancet Haematol. 2025. PMID: 40090352. doi:10.1016/S2352-3026(24)00377-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。